🔗 Share this article Patients Coming Off Weight-Loss Medications Put On Pounds at a Quadrupled Rate Than Those on Conventional Diets Obesity treatment involves ongoing approaches. New research suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs. Published data in a leading medical journal demonstrates that while overweight people frequently drop about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month after stopping. "Individuals purchasing these drugs need to be informed of the danger of fast weight regain when the treatment ends," cautioned expert Dr. Susan Jebb. Such speed of recovery means a reversion to starting weight in about 18 months. Weighing Treatments The research, which examined 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with conventional dieting. Scientists note that individuals who lose weight through diet and exercise typically see a slower creep back—around 100 grams monthly—after stopping. Understanding the Fast Regain Doctors believe the mechanism of the injections is key to understanding the accelerated weight return. The injections imitate a natural hormone called glucagon-like peptide-1, which moderates appetite. "Artificially providing GLP-1 levels far above than normal might result in the system to produce less of its own natural hormone, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher. "Withdrawal of this hormone supplement results in hunger is unsuppressed, making binge eating a significant risk." A Chronic Issue? Medical guidelines advise the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes. A number of clinicians contend that, given the high risk of weight regain, the therapy should be considered life-long. This perspective is echoed by pharmaceutical companies, who say that the findings "emphasize the persistent nature of excess weight," comparing it to managing diseases like diabetes. User Accounts Individuals who have stopped the medication report a sudden resurgence of hunger. "I experienced a switch activating and you're instantly extremely hungry," recalled a patient. The struggle is worsened if patients have not developed lasting dietary or behavioural modifications during therapy. Growing Interest Figures show that millions of adults in the UK have tried weight-loss jabs in the past year, with desire being substantial. Use is more common among females compared to men. The 40s and 50s demographic shows the greatest usage rates. A large proportion access the drugs through private healthcare rather than the NHS. Finally, clinicians caution that while the jabs are effective agents for shedding pounds, they are not a magic solution and long-term success relies on ongoing lifestyle support.
Obesity treatment involves ongoing approaches. New research suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs. Published data in a leading medical journal demonstrates that while overweight people frequently drop about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month after stopping. "Individuals purchasing these drugs need to be informed of the danger of fast weight regain when the treatment ends," cautioned expert Dr. Susan Jebb. Such speed of recovery means a reversion to starting weight in about 18 months. Weighing Treatments The research, which examined 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with conventional dieting. Scientists note that individuals who lose weight through diet and exercise typically see a slower creep back—around 100 grams monthly—after stopping. Understanding the Fast Regain Doctors believe the mechanism of the injections is key to understanding the accelerated weight return. The injections imitate a natural hormone called glucagon-like peptide-1, which moderates appetite. "Artificially providing GLP-1 levels far above than normal might result in the system to produce less of its own natural hormone, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher. "Withdrawal of this hormone supplement results in hunger is unsuppressed, making binge eating a significant risk." A Chronic Issue? Medical guidelines advise the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes. A number of clinicians contend that, given the high risk of weight regain, the therapy should be considered life-long. This perspective is echoed by pharmaceutical companies, who say that the findings "emphasize the persistent nature of excess weight," comparing it to managing diseases like diabetes. User Accounts Individuals who have stopped the medication report a sudden resurgence of hunger. "I experienced a switch activating and you're instantly extremely hungry," recalled a patient. The struggle is worsened if patients have not developed lasting dietary or behavioural modifications during therapy. Growing Interest Figures show that millions of adults in the UK have tried weight-loss jabs in the past year, with desire being substantial. Use is more common among females compared to men. The 40s and 50s demographic shows the greatest usage rates. A large proportion access the drugs through private healthcare rather than the NHS. Finally, clinicians caution that while the jabs are effective agents for shedding pounds, they are not a magic solution and long-term success relies on ongoing lifestyle support.